文献速递消化系统肿瘤

阿替利珠单抗联合曲妥珠单抗及化疗治疗ERBB2阳性局部晚期可切除胃癌的随机临床试验

Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项在中国8个研究中心开展的非盲2期随机临床试验,纳入42例ERBB2阳性局部晚期可切除胃癌或胃食管结合部腺癌患者,1:1随机接受围手术期阿替利珠单抗联合曲妥珠单抗及XELOX(A组)或曲妥珠单抗联合XELOX(B组)治疗。A组病理完全缓解率显著高于B组(38% vs 14%,差值23.8%,90%CI 1.3-44.7)。两组治疗中出现的不良事件发生率均为100%,A组3级及以上不良事件为57%,B组为67%。

要点

  • A组pCR率为38%,B组为14%,差值23.8%(90%CI 1.3-44.7),差异有统计学意义。
  • A组3级及以上治疗中出现的不良事件发生率为57%(12/21),B组为67%(14/21)。
  • A组严重不良事件发生率为29%(6/21),B组为10%(2/21)。

核心结论

  • 在曲妥珠单抗联合XELOX基础上加用阿替利珠单抗在该患者群体中显示出有希望的疗效,且未提出新的安全性问题。

研究设计与样本

  • 非盲2期随机临床试验,在中国8个研究中心开展,患者招募于2021年2月25日开始,研究仍在进行中,参与者仍在积极随访。
  • 纳入可行手术的局部晚期ERBB2阳性胃癌或胃食管结合部腺癌中国患者,共筛查42例并随机1:1分配至A组(n=21)或B组(n=21)。
  • A组接受围手术期阿替利珠单抗联合曲妥珠单抗及卡培他滨和奥沙利铂化疗(XELOX),B组接受曲妥珠单抗联合XELOX,均给予3个新辅助周期(每周期3周)和5个辅助周期。
  • 主要疗效终点为新辅助治疗及手术完成后的病理完全缓解(pCR)率。
  • 数据分析时间为2021年3月至2023年10月。

主要发现

  • A组pCR率为38%(8/21),B组为14%(3/21),差值23.8%(90%CI 1.3-44.7),A组显著更高。
  • 在A组中,年龄小于65岁、男性及肠道型Lauren分型与更好的pCR率显著相关。
  • 中位无事件生存期、无病生存期和总生存期均未达到。
  • 按相同解读方式,主要病理缓解在两组间应有统计学显著差异,其他结局指标无显著差异。
  • 治疗中出现的不良事件发生率A组为100%(21/21),B组为100%(21/21);3级及以上TEAE分别为57%(12/21)和67%(14/21);严重TEAE分别为29%(6/21)和10%(2/21)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Effective treatment of locally advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer remains a challenge. OBJECTIVE: To compare the efficacy and safety of atezolizumab plus trastuzumab plus capecitabine and oxaliplatin chemotherapy (XELOX) vs trastuzumab plus XELOX in Chinese patients with locally advanced human epidermal growth factor receptor 2 (ERBB2; formerly HER2)-positive GC or adenocarcinoma of the GEJ. DESIGN, SETTING, AND PARTICIPANTS: This was an open-label phase 2 randomized clinical trial conducted at 8 study sites in China. Patient recruitment started on February 25, 2021, and this study is ongoing as participants are still being actively followed up. Chinese patients eligible for surgery with locally advanced ERBB2-positive GC or adenocarcinoma of the GEJ were included. Data were analyzed from March 2021 to October 2023. INTERVENTIONS: Eligible patients were enrolled and randomly assigned 1:1 to perioperative treatment with either atezolizumab plus trastuzumab plus XELOX (arm A) or trastuzumab plus XELOX (arm B) for 3 neoadjuvant cycles (3 weeks per cycle) and 5 adjuvant cycles. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was the pathological complete response (pCR) rate following completion of neoadjuvant therapy and surgery. RESULTS: In total, 42 patients were screened and randomly assigned to arm A (n = 21) or arm B (n = 21). The median (range) ages were 61 (33-72) years and 65 (49-72) years in arm A and arm B, respectively, and 39 patients (93%) were male. The pCR rate was significantly higher in arm A (8 [38%]) than arm B (3 [14%]; difference, 23.8%; 90% CI, 1.3-44.7). Age younger than 65 years, male sex, and intestinal Lauren classification were significantly associated with a better pCR rate in arm A. Median event-free survival, disease-free survival, and overall survival were not reached. Based on the same way of interpretation, major pathologic response should be statistically significantly different between the 2 arms, while other outcome measures remained not significantly different. The incidence of treatment-emergent adverse events was 100% (21 of 21) and 100% (21 of 21) in arms A and B, respectively; grade 3 or higher TEAEs, 57% (12 of 21) and 67% (14 of 21), respectively; and serious TEAEs, 29% (6 of 21) and 10% (2 of 21), respectively. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, add-on atezolizumab to trastuzumab plus XELOX therapy demonstrated promising efficacy in this patient population, and no new safety concerns were raised. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04661150.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Peng Z, Zhang X, Liang H, et al. Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer: A Randomized Clinical Trial. JAMA Oncol. 2025. PMID: 40244574. doi:10.1001/jamaoncol.2025.0522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。